|
|
|
|
BioPortfolio Bulletin - Special Announcement |
| www.bioportfolio.com |
www.bioportfolio.co.uk/bulletin_special_7.html October 17, 2002 |
|
| |
In this issue:
|
|
|
|
|
|
BioPortfolio FREE
membership offer Purchase any report stocked by BioPortfolio and receive FREE corporate membership to BioPortfolio worth $300.00. Offer ends October 31st 2002: To view our collection: http://www.bioportfolio.com/cgi-bin/acatalog/ To view BioPortfolio Membership service: http://www.bioportfolio.com/membership_services.htm |
|
|
|
|
|
|
Datamonitor offers FREE report |
|
The therapeutic proteins market grew by 14% in 2001, and is forecast to achieve sales of over $50bn by 2010. This rate of growth is faster than the pharmaceutical industry as a whole. However, there are a number of critical issues that companies must overcome to achieve success, notably the threat of biogenerics and the imminent shortfall in biologics manufacturing capacity.
Find the answers, and much more, in: Therapeutic Proteins: Strategic Market Analysis and Forecasts to 2010. Datamonitor presents a comprehensive and independent evaluation of 13 major therapeutic protein classes. Included is an extensive global and seven country product and class sales analysis, as well as an in-depth evaluation of the commercial potential of the therapeutic protein R&D pipeline. Forecast year-on-year sales for all major products and classes to 2010 are also given. With this analysis, you will be able to:
Order today to take advantage of this special offer!Hurry. Order "Therapeutic Proteins: Strategic Market Analysis and Forecasts to 2010" before October 31st 2002 and receive another report “Therapeutic Proteins: Key Markets and Future Strategies” absolutely FREE! To order this report - click here! - then search by title. To
Order Simply go to: http://www.bioportfolio.com/cgi-bin/acatalog/copy_of_Datamonitor_2002.html
and select the “"Therapeutic
Proteins: Strategic Market Analysis and Forecasts to 2010" ”
report. You will automatically receive the free report “Therapeutic
Proteins: Key Markets and Future Strategies”
with your
order. |
|
|
|
|
|
Urch
Publishing report "European Generics Drug Markets - Growth to
2007" For further details go to: http://www.bioportfolio.com/news/Urch_1.htm To order go to: http://www.bioportfolio.com/cgi-bin/acatalog/search.html and search by title. |
|
|
|
|
|
BioSeeker
report "The next Generation Antifungals: Triazoles vs Peptides" According to the Antifungal Work Group at NIH there is a “critical need for the development of antifungal agents“ (Draft report of the Antifungal Working Group). "There is not a single rapidly fungicidal, non-toxic drug available", they continue, and it is a requirement for fungicidal, broad spectrum, non-toxic, orally deliverable drugs to have a low cost. During the 1990's, the U.S. systemic antifungal market has grown 25% per year. The estimated health care cost of an episode of care for candidemia has been estimated to approximately $35 000 US dollars per Medicare patient (The Fifth NIAID Workshop in Medical Mycology, 2000). And with roughly 30 000 patients with candida nosocomial bloodstream infections per year, annual costs for just candidemia excedes $1bn US. There will be a tight competition for market shares when Pfizer’s patent on fluconazole (the active ingredient in Diflucan™) expires in 2004. Both Bristol-Myers Squibb and Schering-Plough will try to compete for market shares. In this report we present new data on activities in the field of triazole and peptide antifungals. One new triazole (Vfend) and one peptide antifungal (Cancidas) have just been approved by the FDA. There are currently an additional three peptide antifungals compared to only one additional triazole in phase III. Thus one can expect a more straightforward developmental process for the peptide antifungals. However, no additional peptide antifungals are found in phases I or II. Both Vfend and Cancidas are expected to gain $300-500 M US in revenues already 2004. Within a five-year time span there could be at least an additional four triazoles and three peptide antifungals competing on the market. Several novel targets for antifungal therapy are emerging. Most of these are in pre-clinical and phase I studies and will have at least 5-10 years before they reach the market. BioSeeker Group is studying these targets and antifungal discovery platforms closer and will soon publish a supplemental report. Our Highlight Reports are produced to enable our customers to be updated on the progress within different sectors of the biotechnology industry, and will give you access to achievements and novel breakthroughs during the latest years of activities. Apart from the pharma industry itself, this report is of value to investors, science incubators, investigators, contract research organizations or any other types of organization that have an interest in new antifungal therapies. This 53-page report focuses on achievements made in coming therapies for the treatment of fungal infections. Twenty-nine companies are involved in this development. Topics considered in this report are:
Companies included in the report: Anadys Pharmaceuticals, Aressa Pharmaceuticals, AstraZeneca, Aventis (Hoechst Marion Roussel), BioLeads GmbH, Biosearch Italia, Bristol-Myers Squibb, CyDex, Eisai Company Ltd., Eli Lilly, Fujisawa Pharmaceutical Co, GeneData AG, Genome Therapeutics Corp., GPC Biotech, J. Uriach & Cia. S.A., Merck & Co., Microcide, Micrologix, Mycologics, MycoLogics Inc, Pfizer, Phytera, Sankyo Co. Ltd., Schering - Plough, SS Pharmaceutical Co. Ltd., Takeda Chemical Industries Ltd., Toyama Chemical Co. Ltd., Toyo Jozo Co. Ltd, Versicor To order go to: http://www.bioportfolio.com/cgi-bin/acatalog/search.html and search by title. |
|
|
|
|
| Visiongain report "Anti-Infectives 2002" | |
The anti-infectives market is poised to experience considerable growth in the next few years, with a forecast market value that is expected to double in size to more than $44 billion by 2010. Opportunities for investment, research and development in this therapeutic area are rapidly emerging, as market-leading brands such as GlaxoSmithKline's Augmentin face patent expiration, the wrath of new legislation, intense competition from generic copycats and new therapeutic products. This report contains:
Recent FDA approved drugs such as Eli Lilly's Xigris for sepsis has the potential to become a blockbuster product, while pipeline drugs such as AstraZeneca's Oxazolidinone antibiotic could pave the way for a whole new generation of anti-infective drugs. Why you must buy this report
In-depth analysis of market trends, global sales of leading products · Identify the major players, level of competition & hot areas of research · Product pipeline for anti-infective medications of all classes · Global problem of infectious disease & demands for new anti-infective drugs · Profiles of companies with a strong product pipeline & market-leading brand products · Identify hot areas of research & development, and up · Revenue forecast for new FDA approved anti-infective drugs with blockbuster potentials · Projections for the future of the anti-infectives market. This Visiongain report provides you with the most up-to-date and comprehensive guide to the anti-infectives market. With 80+ uniquely compiled tables of facts and figures, 45+ multicolored graphs, company profiles of the key players, new product information, revenue forecasts, market projections, latest news and developments, you must order this 350-page report now? To order go to: http://www.bioportfolio.com/cgi-bin/acatalog/search.html and search by title. |
|
|
|
|
|
BioNewsCast
- getting your news noticed for as low as $25.00 per release BioPortfolio's BioNewsCast service ensures that your press releases are seen quickly by the right audience using all the benefits of internet technologies. This exceptional value-for-money service complements your conventional routes to the media networks. By
using BioPortfolio's BioNewsCast service you will obtain rapid global
distribution through Moreover.com's biotechnology and pharmaceutical
newsfeed and BioPortfolio's BioNews
Search Engine, which are used on thousands of internet sites, by
hundreds of press editors and millions of internet users. PR Agencies can use the service to distribute all their clients press releases subject to the price structure below. Biotechnology and Pharmaceutical companies and service providers can also take advantage of the BioNewsCast service either as an independent service if they have large numbers (>12 Press Releases pa), or, as part of a corporate membership subscription package which includes BioNewsCast. BioNewsCast
Download pdf brochure: http://www.bioportfolio.com/pdf/BioNewsCast.pdf To order go to: http://www.bioportfolio.com/cgi-bin/acatalog/search.html and search for BioNewsCast |
|
|
| |
|
|
BioPortfolio - 14 Channels |
|
| |
| BioPortfolio is the
essential web resource for scientists, executives, investors and the
consumer with an interest in who, what, where, when
and why biotechnology will impact on our lives. We have created
proprietary databases and search engines that will support your business
and private interests in the most exiting technology of the 21st Century. BioPortfolio provides
14
Channels:
BioWeb
and BioNews - Search Engines
- better
than Google? | |
|
Contact
us:
Subscriber information:
To change your subscription to the text based BioPortfolio
Bulletin reply to this email with TEXT in the
subject line.
To unsubscribe, email: Disclaimer: | |